$164.24
0.42% today
NYSE, Sep 16, 08:44 pm CET
ISIN
US23918K1088
Symbol
DVA

DaVita HealthCare Partners Stock price

$163.56
+17.72 12.15% 1M
+25.29 18.29% 6M
+58.80 56.13% YTD
+62.43 61.73% 1Y
+38.96 31.27% 3Y
+101.70 164.40% 5Y
+89.63 121.24% 10Y
NYSE, Closing price Fri, Sep 13 2024
+5.92 3.76%
ISIN
US23918K1088
Symbol
DVA
Sector

Key metrics

Market capitalization $13.72b
Enterprise Value $26.67b
P/E (TTM) P/E ratio 17.41
EV/FCF (TTM) EV/FCF 20.86
EV/Sales (TTM) EV/Sales 2.13
P/S ratio (TTM) P/S ratio 1.10
P/B ratio (TTM) P/B ratio 23.22
Revenue growth (TTM) Revenue growth 6.69%
Revenue (TTM) Revenue $12.52b
EBIT (operating result TTM) EBIT $1.84b
Free Cash Flow (TTM) Free Cash Flow $1.28b
Cash position $523.94m
EPS (TTM) EPS $9.40
P/E forward 16.26
P/S forward 1.07
EV/Sales forward 2.09
Short interest 11.12%
Show more

Is DaVita HealthCare Partners a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

DaVita HealthCare Partners Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a DaVita HealthCare Partners forecast:

1x Buy
10%
7x Hold
70%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a DaVita HealthCare Partners forecast:

Buy
10%
Hold
70%
Sell
20%

Financial data from DaVita HealthCare Partners

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,187 3,187
6% 6%
100%
- Direct Costs 2,318 2,318
4% 4%
73%
869 869
14% 14%
27%
- Selling and Administrative Expenses 192 192
7% 7%
6%
- Research and Development Expense - -
-
-
677 677
17% 17%
21%
- Depreciation and Amortization 176 176
4% 4%
6%
EBIT (Operating Income) EBIT 501 501
26% 26%
16%
Net Profit 223 223
25% 25%
7%

In millions USD.

Don't miss a Thing! We will send you all news about DaVita HealthCare Partners directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DaVita HealthCare Partners Stock News

Neutral
PRNewsWire
3 days ago
DENVER , Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer.
Positive
Investors Business Daily
6 days ago
Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are the five top-performing stocks to buy now or put on a watchlist.
Positive
24/7 Wall Street
8 days ago
Warren Buffett has obliterated the market's returns since becoming CEO of Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B) in the mid-1960s.
More DaVita HealthCare Partners News

Company Profile

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Head office United States
CEO Javier Rodriguez
Employees 70,000
Founded 1994
Website www.davita.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today